$11.18
0.13% today
Nasdaq, Feb 05, 04:22 pm CET
ISIN
US2928121043
Symbol
ENFN

Enfusion Stock price

$11.19
+0.78 7.49% 1M
+2.54 29.36% 6M
+0.89 8.64% YTD
+3.36 42.91% 1Y
-2.80 20.01% 3Y
-8.62 43.51% 5Y
-8.62 43.51% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.04 0.36%
ISIN
US2928121043
Symbol
ENFN

Key metrics

Market capitalization $1.06b
Enterprise Value $1.06b
P/E (TTM) P/E ratio 427.10
EV/FCF (TTM) EV/FCF 52.97
EV/Sales (TTM) EV/Sales 5.41
P/S ratio (TTM) P/S ratio 5.41
P/B ratio (TTM) P/B ratio 14.93
Revenue growth (TTM) Revenue growth 15.78%
Revenue (TTM) Revenue $195.16m
EBIT (operating result TTM) EBIT $6.71m
Free Cash Flow (TTM) Free Cash Flow $19.92m
Cash position $48.30m
EPS (TTM) EPS $0.03
P/E forward 217.45
P/S forward 5.21
EV/Sales forward 5.20
Short interest 1.55%
Show more

Is Enfusion a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Enfusion Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Enfusion forecast:

5x Hold
83%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Enfusion forecast:

Hold
83%
Sell
17%

Financial data from Enfusion

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
195 195
16% 16%
100%
- Direct Costs 64 64
16% 16%
33%
131 131
16% 16%
67%
- Selling and Administrative Expenses 88 88
26% 26%
45%
- Research and Development Expense 26 26
37% 37%
13%
17 17
30% 30%
9%
- Depreciation and Amortization 11 11
22% 22%
5%
EBIT (Operating Income) EBIT 6.71 6.71
40% 40%
3%
Net Profit 3.34 3.34
43% 43%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Enfusion directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enfusion Stock News

Neutral
PRNewsWire
20 days ago
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Enfusion, Inc. (NYSE: ENFN)'s  sale to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock. If ...
Neutral
GlobeNewsWire
21 days ago
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
Business Wire
23 days ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics Holdings, Inc. (NYSE: CWAN). Under the terms of the proposed transaction, shareholders of Enfusion will receive $5.85 in cash and $5.40 in Clearwater Class A Com...
More Enfusion News

Company Profile

Enfusion, Inc. engages in the development of cloud-native multi-tenant software for alternative and institutional investment managers. It is a software-as-a-service firm that develops platform to eliminate technology and information barriers, and simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset. The company was founded in 2006 and is headquartered in Chicago, IL.

Head office United States
CEO Oleg Movchan
Employees 1,102
Founded 2006
Website enfusion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today